Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Brugarolas

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Kidney International|November 26, 1999
The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathyM Al-Douahji, J Brugarolas, P A Brown, et al.
Actas Urologicas Espanolas|July 20, 2007
[Polyarthritis secondary to intravesical BCG instillation, a case report]A Rincón Mayans, J J Zudaire Bergera, J Brugarolas Rosselló, et al.
Nature Genetics|August 1, 1997
Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethalityR Montes de Oca Luna, L L Amelse, A Chavez-Reyes, et al.
Anales Del Sistema Sanitario De Navarra|May 4, 2012
[Radical prostatectomy for high risk localized prostate cancer. Prognosis and study of influential variables]A Rincón Mayans, B Zudaire, J Brugarolas, et al.
Oncogene|January 11, 2011
Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic deathB Kucejova, N E Sunny, A D Nguyen, et al.
Oncogene|March 4, 2026
Correction: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
Oncogene|February 16, 2016
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Kidney International|November 26, 1999
The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathyM Al-Douahji, J Brugarolas, P A Brown, et al.
Actas Urologicas Espanolas|July 20, 2007
[Polyarthritis secondary to intravesical BCG instillation, a case report]A Rincón Mayans, J J Zudaire Bergera, J Brugarolas Rosselló, et al.
Nature Genetics|August 1, 1997
Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethalityR Montes de Oca Luna, L L Amelse, A Chavez-Reyes, et al.
Anales Del Sistema Sanitario De Navarra|May 4, 2012
[Radical prostatectomy for high risk localized prostate cancer. Prognosis and study of influential variables]A Rincón Mayans, B Zudaire, J Brugarolas, et al.
Oncogene|January 11, 2011
Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic deathB Kucejova, N E Sunny, A D Nguyen, et al.
Oncogene|March 4, 2026
Correction: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
Oncogene|February 16, 2016
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Pageof 2